In a move set to redefine the landscape of women’s healthcare in Southeast Asia, DKSH Business Unit Healthcare Thailand and the global life science giant Bayer Thai have officially announced the expansion of their strategic partnership. This enhanced collaboration, finalized on April 1, 2026, focuses on a comprehensive commercialization model designed to broaden access to critical endometriosis treatments. By integrating DKSH’s robust market expansion capabilities with Bayer’s innovative pharmaceutical portfolio, the two entities aim to address significant unmet medical needs for women across the Kingdom.
This expanded agreement transitions the relationship into a full-service commercialization partnership, where DKSH will now manage the end-to-end journey of Bayer’s endometriosis therapies in the Thai market. The scope of services includes large-scale distribution, strategic promotion, medical engagement with healthcare professionals, and ensuring nationwide market access through various clinical channels. This development marks a significant milestone in DKSH’s mission to provide patient-centric healthcare solutions while supporting the long-term, sustainable growth of its international partners.
The decision to deepen this alliance is rooted in a history of successful collaboration and high-performance execution. Following several months of exceptional commercial results in the Thai market, Bayer chose to increase the scope of DKSH’s responsibilities, underscoring a deep-seated confidence in their partner’s logistical and medical infrastructure. This partnership is not merely a business transaction but a strategic alignment aimed at strengthening the Thai healthcare ecosystem and improving the overall quality of life for patients seeking non-surgical therapeutic options.
Bridging the Gap in Women’s Health and Endometriosis Treatment
The expansion of this partnership arrives at a critical juncture for women’s health in Thailand, where endometriosis remains a widespread yet often underdiagnosed condition. Medical data indicates that endometriosis affects approximately 5-10% of the general female population, but the prevalence skyrockets to 60-80% among women suffering from chronic pelvic pain or severe dysmenorrhea. Despite these high numbers, many patients continue to face significant barriers to timely diagnosis and high-quality care, leading to prolonged physical and emotional distress.
By leveraging DKSH’s extensive network, which spans across major hospitals, specialist Obstetrics and Gynecology clinics, and retail pharmacies, the collaboration aims to ensure that treatment is available wherever patients seek help. The primary goal is to target disease progression and manage symptoms more effectively, offering a long-term medical alternative for women who may wish to avoid or delay surgical intervention. This patient-first approach is central to the strategy, focusing on making innovative treatments accessible regardless of the patient’s geographic location within the country.
The strategic importance of this initiative is further highlighted by the growing demand for specialized women’s healthcare services in Thailand. As the “Women’s Health” segment continues to be a primary growth driver in the regional pharmaceutical industry, the synergy between DKSH and Bayer positions both companies to lead the market. By closing the access gaps that currently exist in the healthcare system, the partnership intends to foster a more sustainable and equitable environment for women’s medical services, ensuring that high-quality treatments are a standard of care rather than a luxury.
Strategic Commercial Execution and Market Expansion
DKSH’s role as a leading Market Expansion Services provider is pivotal to the success of this partnership, offering a sophisticated blend of sourcing, marketing, and logistics. Under the new agreement, DKSH will utilize its “deep local expertise” and “strong medical and commercial infrastructure” to drive the adoption of Bayer’s endometriosis therapies. This includes a data-driven approach to medical engagement, where DKSH specialists work closely with Thai physicians to provide the latest clinical information and ensure the best outcomes for patients.
The infrastructure supporting this expansion is massive, involving DKSH’s 7,580 specialists within the Healthcare Business Unit who are dedicated to distributing pharmaceuticals and medical devices. In 2025 alone, DKSH Business Unit Healthcare generated net sales of CHF 5.8 billion, demonstrating the financial and operational scale required to manage such a significant portfolio for a company like Bayer. This scale allows for a nationwide reach that few other partners can offer, ensuring that even remote clinics have access to the same high-quality treatments found in Bangkok’s top-tier hospitals.
Furthermore, the collaboration is built on a “proven capability” framework, where Bayer relies on DKSH to execute complex market strategies that align with global standards while adapting to local nuances. This includes navigating the regulatory landscape and market access protocols in Thailand, which can be complex for international firms to manage independently. By trusting DKSH with these responsibilities, Bayer can focus on its core competencies of research and development, knowing that its commercial footprint in Thailand is in capable hands.
Leadership Perspectives on Social Impact and Growth
The leadership of both organizations has emphasized that this expansion is driven by a dual purpose: business excellence and social responsibility. Ashraf Al-Ouf, President & Representative Director at Bayer Japan and Head of Commercial Operations APAC for Pharmaceuticals, highlighted that the partnership is a testament to the trust built through consistent performance. He noted that the collaboration is fundamentally about improving the lives of women living with endometriosis by ensuring they have reliable access to the quality care they deserve.
“We are pleased to expand our partnership with DKSH in Thailand. In a short time, they’ve shown strong commercial execution and a real understanding of the local market, reinforcing our trust in them as a partner. This expansion is not just about business; it is about improving access to women’s healthcare, especially for those living with endometriosis. Our collaboration aims to ensure more women in Thailand can access the quality treatment they deserve.” — Ashraf Al-Ouf, President & Representative Director at Bayer Japan & Head of Commercial Operations APAC, Pharmaceuticals.
Echoing this sentiment, Patrik Grande, Head of Business Unit Healthcare at DKSH, reiterated the company’s commitment to addressing “unmet needs” in the healthcare sector. He explained that by combining DKSH’s integrated solutions with Bayer’s specialized women’s health portfolio, the two companies could deliver a “meaningful impact” for patients across the nation. Grande emphasized that the mission is to close existing access gaps and strengthen the overall sustainability of the Thai healthcare system through timely and quality treatment.
“Through this collaboration, we aim to help improve access to treatment as part of our mission to deliver better healthcare for all. By leveraging our extensive distribution network and commercial expertise, we aim to help close these access gaps, and enable more Thai women to receive timely, quality treatment, while strengthening the sustainability of the healthcare system. We are proud that Bayer has chosen to deepen our collaboration based on our performance.” — Mr. Patrik Grande, Head of Business Unit Healthcare, DKSH.
Corporate Foundations and Financial Strength
Bayer’s involvement in this partnership is backed by its global reputation as a leader in life sciences, specifically in the fields of healthcare and nutrition. With a mission of “Health for all, Hunger for none,” the company invested 5.8 billion euros in research and development in 2025 to address global challenges such as aging populations and chronic diseases. In fiscal 2025, Bayer employed approximately 88,000 people worldwide and recorded sales of 45.6 billion euros, underscoring its capacity to innovate and deliver value on a global scale.
DKSH, with a history spanning over 160 years, brings a different but equally vital strength to the table: an unparalleled understanding of the Asia-Pacific market. As a participant in the United Nations Global Compact, DKSH adheres to a principle-based approach to responsible business while operating in 35 markets with over 26,000 specialists. The company’s 2025 net sales reached CHF 11.1 billion, and its listing on the SIX Swiss Exchange highlights its stability and attractiveness to global pharmaceutical partners looking for a reliable gateway into Asia.
Together, these two powerhouses are laying a foundation for a more resilient healthcare landscape in Thailand. By focusing on reliable and equitable access to high-quality healthcare products, the partnership between DKSH and Bayer is poised to improve the quality of life for thousands of women. This strategic alliance not only reinforces DKSH’s role as a long-term regional partner but also sets a new standard for how international and local expertise can collaborate to solve some of the most pressing health issues of the modern era.
#Endometriosis #WomensHealth #DKSH #Bayer #HealthcareThailand #MedicalInnovation #Pharmaceuticals #StrategicPartnership #PublicHealth #ThailandBusiness #MarketExpansion
